NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 3 hours 53 min ago
Notice of NIAID Research Objectives added to PAR-18-714 Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed)
Notice NOT-AI-19-038 from the NIH Guide for Grants and Contracts
Notice of NIAID Research Objectives added to PAR-19-134 Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
Notice NOT-AI-19-037 from the NIH Guide for Grants and Contracts
NCI Awardee Skills Development Consortium: Research Education Short Courses (UE5 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-19-010 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Cancer Institute (NCI) UE5 R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical cancer research needs. This UE5 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)." The major objective of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers
NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-19-011 from the NIH Guide for Grants and Contracts. This U24 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)." The overarching goal of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers. This U24 FOA solicits applications for a Coordinating Center to address the NASDC logistics and evaluation needs in serving the NASDC Research Education Short Courses that will be supported by a companion UE5 FOA RFA-CA-19-010). The various logistic and evaluation activities and roles of the U24 NASDC Coordinating Center include, but are not limited to, working together with the UE5 Research Education Short Course awardees on advertising the NASDC Short Courses and recruiting participants; providing logistic support during course implementation; arranging periodic NASDC Steering Committee in-person meetings and teleconferences and preparing summary minutes; and assuming a primary role in the evaluation of the NASDC Courses and overall program.
Notice of Clarification in Eligibility Requirements for PAR-19-098 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) and PAR-19-051 Emerging Global Leader Award (K43 Independent Clinical Trial Required)
Notice NOT-TW-19-002 from the NIH Guide for Grants and Contracts
Notice of Change to Award Information in RFA-CA-19-032 "Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)"
Notice NOT-CA-19-024 from the NIH Guide for Grants and Contracts
Notice of Correction to PA-17-148, Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42)
Notice NOT-MH-19-012 from the NIH Guide for Grants and Contracts
Notice of Information: Report on Site Visits to the Veterans Affairs Medical Centers with Focus on Canine Care and Use in Research
Notice NOT-OD-19-069 from the NIH Guide for Grants and Contracts
Notice for a Pre-application Webinar for Funding Opportunity Announcement PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)"
Notice NOT-CA-19-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-18-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications for the George M. OBrien Urology Cooperative Research Centers Program (U54). This program will foster multi- and interdisciplinary collaboration between basic, translational, and clinical researchers with diverse expertise to address questions of underlying etiology and biological and clinical features of benign genitourinary conditions within the NIDDKs mission. In addition, the program will serve as a national resource for the larger urologic research community and provide opportunities for educational enrichment and engagement of investigators from urology and other, broad disciplines. All efforts will address the overall goal of improving prevention and clinical management of benign genitourinary disorders through research excellence, enhanced sharing of resources, and establishment of a robust research community.
Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional)
Funding Opportunity RFA-DK-18-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist MDs, PhDs, and MD/PhDs with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (http://www2.niddk.nih.gov/Research/ScientificAreas/Urology/). This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Patient Safety Learning Laboratories (2019): Pursuing Safety in Diagnosis and Treatment at the Intersection of Design, Systems Engineering, and Health Services Research (R18)
Funding Opportunity RFA-HS-19-001 from the NIH Guide for Grants and Contracts. This R18 Request for Application (RFA) calls for the creation and utilization of Patient Safety Learning Laboratories. These learning laboratories are places and networks where transdisciplinary teams identify closely related threats to diagnostic or treatment efforts associated with a high burden of harm and cost. Following a systems engineering methodology, the learning laboratories stretch professional boundaries, envision innovative designs, and take advantage of brainstorming and rapid prototyping techniques that other leading industries employ. Promising prototypes undergo further develop-test-revise iterations, and subsequent integration as a working system. After further improvements are made to the integrated working system, its efficacy is evaluated in a realistic simulated or clinical setting
Notice NOT-HS-19-010 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-178 from the NIH Guide for Grants and Contracts. The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000, after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000.
Funding Opportunity PAR-19-179 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems. The minimum award is $50,000. There is no maximum price requirement; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass and nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
Funding Opportunity PAR-19-175 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium.
Funding Opportunity RFA-AI-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation to validate and improve the utility and robustness of the computational models. Another goal of this FOA is to make the computational models and data developed under this initiative readily available to the broader research community for further refinement or direct use in biological experimentation. This program will also support workshops and symposia to foster the use of computational models of immunity by the broader research community.
Patient Reported Outcomes Tool Development for Use in Non-Cystic Fibrosis Bronchiectasis Clinical Trials (U01) Clinical Trial Optional
Funding Opportunity RFA-FD-19-005 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research to develop and qualify a Patient Reported Outcome (PRO) for Non-Cystic Fibrosis Bronchiectasis (NCFB) under FDAs Drug Development Tools Qualification Program. This would include the qualitative phase of developing the instrument, quantitative phase of testing the instrument, and qualification of the instrument. It is expected that this qualified PRO would help improve upon the current design, conduct, and interpretation of anti-infective clinical trials in NCFB patients, for which optimal endpoints are currently lacking. This work directly aligns with FDAs research area of interest to stimulate innovation in clinical evaluations and personalized medicine to improve product performance and patient outcomes."
Notice of Participation of the Office of Research on Womens Health (ORWH) in RFA-HG-19-004, Human Genome Reference Center (HGRC) (U41 Clinical Trial Not Allowed)
Notice NOT-OD-19-068 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-19-002 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) seeks applications for the production of High Quality Human Reference Genomes (HQRG) as a component of the NHGRI Human Genome Reference Program (HGRP). One aim of the HGRP is to develop a genome reference that is representative of human population genetic diversity. To help achieve this goal, this HQRG initiative is expected to establish metrics for high quality-genome assemblies; collaborate with other HGRC awardees on sample selection and prioritization; produce on the order of 350 haplotype-resolved human genomes, using diverse samples consented for full data release; and provide capacity to help resolve error reports received by the HGRC. This and related FOA's will replace and update NHGRI's current contributions to the Genome Reference Consortium https://www.ncbi.nlm.nih.gov/.
NIH Funding Opportunities
- Development, Implementation, and Management of a Funding System to support the Grade A Milk Safety Program and National Shellfish Sanitation Program (U18)
- Notice of Correction to RFA-CA-19-008 "The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trial Not Allowed)"
- Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)
- Notice of Removal of Matching Requirement Instructions for RFA-EB-18-003 "HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)"
- Notice of Intent to Publish a Funding Opportunity Announcement for Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)